Martin Harp

Ocugen's OCU410 gene therapy shows promising results in reducing lesion growth for geographic atrophy, potentially transforming treatment for retinal health.

Alcon noted additional operational updates alongside the announcement.

At 12 weeks posttreatment, all 4 of the patients showed improvement in the form of a lower logMAR.

The company is developing a one-time, non-AAV2 gene replacement therapy to restore, treat, and prevent blindness of patients with RPE65 mutation-associated retinopathies.